Abstracts

Citation

Ross E. McKinney, Jr., M.D., Mobeen H. Rathore, M.D., ChengCheng Hu, Ph.D., Paula Britto, M.S., Ruth E. Dickover, Ph.D., Diane Claire Smith, B.A., M.T. (A.S.C.P.), Adriana Weinberg, M.D. Phase I/II study of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: PACTG proctol 1021. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Allison George Agwu, M.D., Kimberly Ferguson, Jane C. Lindsey, Sc.D., Maureen M. Goodenow, Ph.D., Steven D. Douglas, M.D., Bret J. Rudy, M.D., Stephen A. Spector, M.D., Patricia M. Flynn, M.D., M.S., Deborah Persaud, M.D. Drug resistance mutations in HIV-1 infected adolescents maintained on initial HAART despite treatment failure. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Sharon Appelbaum Nachman, M.D., Myron Levin, M.D., Lin-Ye Song, Ph.D., Adriana Weinberg, M.D., Robert Walker, M.D. Phase I/II randomized trial of the safety and immunogenicity of cold adapted influenza vaccine (CAIV) vs. inactivated influenza vaccine (IAIV) in HIV infected (HIV+) children; PACTG 1057. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

John H. Rodman, Pharm.D., Patricia M. Flynn, M.D., M.S., David E. Shapiro, Ph.D., Arlene D. Bardeguez, M.D., M.P.H., F.A.C.O.G., Sharon Huang, M.S., Susan A. Fiscus, Ph.D., Koen Van Rompay, D.V.M., Ph.D., James F. Rooney, M.D., Lynne M. Mofenson, M.D., F.A.A.P., Patrick Jean-Philippe, M.D. Pharmacokinetics (PK) and safety of tenofovir disoproxil fumarate (TDF) in HIV-1 infected pregnant women and their infants. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Pearl Samson, M.S., Richard M. Rutstein, M.D., Terence Fenton, Ed.D., Jennifer J. Kiser, Pharm.D., Courtney V. Fletcher, Pharm.D., Steven M. Schnittman, M.D., Lynne M. Mofenson, M.D., F.A.A.P., Elizabeth (Betsy) Smith, M.D., Bobbie L. Graham, B.S., Grace M. Aldrovandi, MD. Changes in cholesterol (CH) and triglyceride (TG) levels among pediatric patients treated with atazanavir (ATV), with/without ritonavir boosting (RTV), the 1020A NIH PACTG protocol. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

John Sabo, M.S., Pedro E. Cahn, M.D., Marinella Della Negra, Ph.D., Guido Castelli-Gattinara, Claudia Fortuny, Ram Yogev, M.D., Juan Carlos Salazar, M.D., M.P.H., Chan-Loi Yong, Jaromir Mikl, Ante Jelaska, M.D. Population pharmacokinetic (PK) assessment of systemic steady-state tipranavir (TPV) concentrations for HIV+ pediatric patients administered tipranavir/ritonavir (TPV/r) 290/115 mg/m^2 and 375/150 mg/m^2 BID (BI 1182.14 and PACTG 1051 study team). Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Allison George Agwu, M.D., Kimberly Ferguson, Jane C. Lindsey, Sc.D., Steven D. Douglas, M.D., Bret J. Rudy, M.D., Stephen A. Spector, M.D., Patricia M. Flynn, M.D., M.S., Deborah Persaud, M.D. Analysis of HIV-1 drug resistance and immune outcomes in HIV-1 infected youth failing initial HAART. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

William Borkowsky, M.D., Ram Yogev, M.D., Petronella Muresan, M.S., Elizabeth (Betsy) J. McFarland, M.D., Lisa M. Frenkel, M.D., Terence Fenton, Ed.D., John ( Jack ) Moye, Jr., M.D., Edmund Capparelli, Pharm.D., Nina Ellis, B.S., Barbara E. Heckman, B.S. Repeated supervised treatment interruptions (STI) with progressive increases in "off treatment" duration results in enhanced virologic control in a subset of pediatric individuals. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Mark Mirochnick, M.D., Karin Alvarenga-Hyldgaard Nielsen, M.D., M.P.H., Jose Henrique Pilotto, M.D., Jorge Pinto, M.D., D.Sc., Eleanor Jimenez, M.D., F.A.A.P., Valdilea V. Santos, M.D., Ph.D., Teresa Parsons, Ph.D., Heather D. Watts, M.D., John ( Jack ) Moye, Jr., M.D., Yvonne J. Bryson, M.D. Nevirapine (NVP) pharmacokinetics (PK) with an extended prophylactic regimen during the first two weeks of life. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Akihiko Saitoh, M.D., Terence Fenton, Ed.D., Carmelita Alvero, Courtney V. Fletcher, Pharm.D., Stephen A. Spector, M.D. Didanosine lowers mitchondrial DNA levels in peripheral blood mononuclear cells in HIV-1 infected children receiving HAART. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.